Global research efforts to slow, stop, or cure Parkinson’s are advancing, driven by innovative science and international collaboration.

Researchers are delving into the condition’s genetic and molecular underpinnings. Understanding this is crucial for developing therapies that can halt or reverse progression.

What kinds of research do they do on Parkinson’s?

Research on Parkinson’s in Australia and internationally spans a wide range of areas, aiming to improve diagnosing, understanding, treatment, and quality of life for those affected.

Research in Australia

  1. Genetics and Molecular Biology: Australian researchers are investigating genetic factors, such as mutations in the PINK1 and LRRK2 genes, which are linked to Parkinson’s. Recent breakthroughs include visualising the structure of the PINK1 protein, which could lead to targeted drug therapies.
  2. Clinical Trials: The Australian Parkinson’s Mission conducts clinical trials to test personalised treatments based on genomic data.
  3. Neuroprotection: Studies focus on protecting neurons from degeneration, exploring compounds that may slow disease progression.
  4. Symptom Management: Research includes developing better therapies for motor and non-motor symptoms, such as tremors, sleep disturbances, and cognitive decline.

International Research

  1. Global Prevalence and Projections: Studies predict a doubling of Parkinson’s cases by 2050, driven by ageing populations and environmental factors.
  2. Environmental Risk Factors: Research explores the role of pesticides, air pollution, and other toxins in increasing Parkinson’s risk.
  3. Immunology and Inflammation: International teams are studying how immune responses, such as T-cell activity, contribute to neuronal damage in Parkinson’s.
  4. Advanced Therapies: Efforts include developing stem cell therapies, gene editing techniques, and brain-computer interfaces to restore motor function.

Alternative Medications

  1. Natural Remedies: Some individuals explore supplements like coenzyme Q10, green tea extract, and alpha-lipoic acid for their antioxidant properties. However, evidence supporting their efficacy in Parkinson’s is limited.
  2. Cannabidiol (CBD): CBD oil is being studied for its potential to alleviate non-motor symptoms like anxiety and sleep disturbances.
  3. Dietary Adjustments: High-protein diets can interfere with levodopa absorption, so timing protein intake strategically may help improve medication efficacy.

Repurposed Medications

  1. Amantadine: Originally developed for influenza, amantadine is now used to manage dyskinesia in Parkinson’s.
  2. Simvastatin: This cholesterol-lowering drug is being investigated for its potential neuroprotective effects in Parkinson’s.
  3. Exenatide: A diabetes medication, exenatide, is under study for its ability to slow disease progression.

New Delivery Methods for Carbidopa/Levodopa

  1. Continuous Infusion Pumps: Innovations like the PRODUODOPA and VYALEV pumps deliver levodopa continuously under the skin, reducing “off” times and motor fluctuations.
  2. Inhalable Levodopa: Inhalable formulations provide rapid relief for sudden “off” episodes, offering a convenient alternative to oral medications.
  3. Extended-Release Tablets: New formulations aim to provide more stable dopamine levels throughout the day.

Key Dates and History of Parkinson’s Research Discoveries

Early Descriptions and Naming

  • 1817: British apothecary James Parkinson publishes “An Essay on the Shaking Palsy,” describing the condition that would later bear his name.
  • 1865: The term “Parkinson’s disease” is coined by William Sanders and later popularised by French neurologist Jean-Martin Charcot.

Mid-20th Century Breakthroughs

  • 1960: Arvid Carlsson discovers the role of dopamine in Parkinson’s, leading to the development of Levodopa therapy.
  • 1967: The Hoehn and Yahr scale is introduced to describe the progression of Parkinson’s.
  • 1969: The first double-blind trial of Levodopa is conducted, showing significant relief of Parkinson’s symptoms.

Late 20th Century Advances

  • 1971: The first double-blind clinical trial of carbidopa/levodopa (Sinemet®) is published, establishing it as the gold-standard therapy for Parkinson’s.
  • 1984: The Parkinson Study Group is established to advance clinical trials and accelerate drug development.
  • 1997: The breakthrough discovery of alpha-synuclein, the first gene associated with Parkinson’s, is made.

21st Century Developments

  • 2009: The Parkinson’s Outcomes Project is launched, becoming the largest-ever clinical study of Parkinson’s with more than 13,000 participants in four countries.
  • 2024: The Vyalev pump, the first subcutaneous 24-hour infusion of foslevodopa/foscarbidopa, is approved by the TGA.

What organisations do research in Australia on Parkinson’s?

Parkinson’s Australia: We support research efforts and provide resources for people living with Parkinson’s. We collaborate with researchers to advance understanding and treatment of the disease through advocacy and recruitment.

Garvan Institute of Medical Research: The Garvan Institute conducts multidisciplinary research on Parkinson’s, including genetic studies and clinical trials. They lead the Australian Parkinson’s Mission, which combines genomics and biomarker technologies to develop personalised treatments. Explore their work here.

Australian Parkinson’s Mission (APM): A collaborative initiative involving the Garvan Institute, Shake It Up Australia Foundation, and international partners like the Michael J. Fox Foundation. APM focuses on precision medicine and clinical trials to slow or stop Parkinson’s progression. More details are available here.

NeuRA (Neuroscience Research Australia): NeuRA focuses on understanding and slowing the progression of Parkinson’s disease. Their research includes investigating genetic factors that predispose people to Parkinson’s. Exploring how brain cells generate energy and ways to improve this function to slow neurodegeneration. Studying the spread of disease-related proteins and strategies to reduce their growth.

CMAX: CMAX is one of Australia’s largest early-phase clinical trial facilities. They conduct trials for new Parkinson’s treatments, such as testing potential therapies for motor and non-motor symptoms and xploring innovative drug delivery methods to improve patient outcomes.

Parkinson’s Organisations

Parkinson’s Australia: Is the national advocacy body promoting awareness and connection for people with Parkinson’s and lobbying government on issues that affect the Parkinson’s community.
State/Territory Parkinson’s organisations: Provides support, information, and advocacy for individuals and families affected by Parkinson’s.

Universities

  • University of Sydney: Collaborates with the Australian Parkinson’s Mission (APM) on clinical trials, genomics research, and biomarker analysis to develop precision medicine for Parkinson’s.
  • QIMR Berghofer Medical Research Institute: Runs the Australian Parkinson’s Genetics Study, investigating genetic and environmental factors contributing to Parkinson’s.
  • Macquarie University: Hosts researchers like Professor Simon Lewis, who leads clinical trials and studies targeting disease progression.
  • Griffith University:
  • Shake It Up Foundation for Parkinson’s Research
  • Brain Foundation https://brainfoundation.org.au/
  • Universities
  • Clinical trials, e.g. CMAX
  • Parkinson’s organisations often do surveys to collect feedback from the community.

Infosheet under review

References

  • Parkinson, J. (1817). An Essay on the Shaking Palsy. The Journal of Neuropsychiatry and Clinical Neurosciences, 14(2), 223-236.
  • Charcot, J.-M. (1865). Lectures on the Diseases of the Nervous System. The Lancet, 86(2209), 1-7.
  • Carlsson, A. (1960). The Occurrence, Distribution and Physiological Role of Catecholamines in the Nervous System. Pharmacological Reviews, 11(2), 490-493.
  • Hoehn, M. M., & Yahr, M. D. (1967). Parkinsonism: onset, progression, and mortality. Neurology, 17(5), 427-442. https://doi.org/10.1212/WNL.17.5.427 :
  • Cotzias, G. C., Van Woert, M. H., & Schiffer, L. M. (1969). Aromatic amino acids and modification of parkinsonism. New England Journal of Medicine, 280(7), 337-345.
  • Marsden, C. D., & Parkes, J. D. (1971). Success and problems of long-term levodopa therapy in Parkinson’s disease. The Lancet, 297(7719), 345-349.
  • Parkinson Study Group. (1984). Clinical trials in Parkinson’s disease: a review. Movement Disorders, 4(2), 93-100.
  • Polymeropoulos, M. H., Lavedan, C., Leroy, E., Dehejia, A., Dutra, A., Pike, B., … & Nussbaum, R. L. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science, 276(5321), 2045-2047.
  • Parkinson’s Outcomes Project. (2009). Largest-ever clinical study of Parkinson’s disease. Parkinson’s Foundation. Retrieved from Parkinson’s Foundation
  • Vyalev: Uses, Dosage, Side Effects, Warnings. (2024). Drugs.com. Retrieved from Drugs.com